Category Archives: Deals

Pfizer Adds FoldRx to its Specialty Care Unit

By George Koroneos | Published: September 1, 2010
Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money. Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become Pfizer [...]
Also posted in Strategy | Tagged , , | Leave a comment

Genzyme Snubs Sanofi Offer

By George Koroneos | Published: August 31, 2010
Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it. “Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
Posted in Deals | Tagged , , | Leave a comment

Astellas and OSI Come Together

By Oriana Schwindt | Published: May 19, 2010
The months-long saga is finally over: Astellas’ enhanced offer of $57.50 a share—around $4 billion—has finally netted it Melville, NY-based OSI Pharmaceuticals. The Japan-based pharma first extended an acquisition offer of $52 per share ($3.5 billion) to OSI on March 1, only to be met with a resounding “Nay” from the board, which said $52 [...]
Also posted in News, Strategy | Tagged , , , , , , | Leave a comment

Is There Life After Big Pharma?

By Julian Upton | Published: March 11, 2010
Guest blog by Pharm Exec Europe’s Jacky Law. It’s hard to get precise figures of how many people have been taken off the payroll at pharma and biotech companies recently. According to staffing firm, Challender, Gray and Christmas, the combined industries shed 58,969 jobs in the first nine months of 2009, 15,000 more than the whole [...]
Also posted in Corporate Responsibility, Europe, Global, Guest Blog | Tagged , , , , , | Leave a comment

GSK Signs $120M Deal to Market DMab Overseas

By George Koroneos | Published: July 29, 2009
Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval. GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]
Also posted in News, Technology | Tagged , , , , , , , , , , , | Leave a comment